AR101
Peanut Allergy
Phase 3Acquired (Development status uncertain)
Key Facts
Indication
Peanut Allergy
Phase
Phase 3
Status
Acquired (Development status uncertain)
Company
About Aytu BioScience
Aytu BioScience is a commercial-stage biopharmaceutical company with a mission to identify, acquire, and commercialize novel therapeutics for patients with high unmet medical needs. Its strategy centers on building a diversified portfolio of commercial products and late-stage development candidates, primarily in rare pediatric and central nervous system disorders. The company generates revenue from its commercial assets while advancing its pipeline to drive future growth. Aytu's focus on underserved markets aims to create significant value for patients and shareholders.
View full company profileTherapeutic Areas
Other Peanut Allergy Drugs
| Drug | Company | Phase |
|---|---|---|
| Peanut Allergy Program | ALK Abello | Development |